Treating Psychiatric Disorders with Psychedelics: A Case Series Review at Cannabis Science Conference East 2022
In his presentation for the psychedelics track at Cannabis Science Conference East 2022, James Schwartz, BSN, LNC, presented “A New Beginning for an Old Therapy: Case Series Review on the Treatment of PTSD and Other Psychiatric Disorders with Psilocybin and Other Psychedelics.” He reviewed the current research and clinical trials studying the effects of psilocybin, plus side effects, potential uses, latest trends, disorders currently being studied, and potential future applications. Schwartz was a trauma trained nurse who worked in the Trauma/Critical Care ICU at Oregon Health and Science University. He is an experienced medical legal consultant and CEO of Cascade High. Here are some highlights from his session.
On day two of the psychedelics track at the Cannabis Science Conference East 2022, James Schwartz, BSN, LNC gave a presentation on the science and application of psychedelics for treating post-traumatic stress disorder (PTSD) and depression. Schwartz first explained the definitions of trauma and PTSD, how the brain uses predictive coding to interpret environments, how trauma is stored in the brain, and how psychedelics touch on all these concepts and can help brain function and increase neuroplasticity. Guided therapy is important, he noted, in the pre- and post-stages of treatments to help the patient explore and process their triggers and memories.
He then outlined several double-blind randomized trials on using psilocybin and other psychedelics as a treatment for PTSD or depression and explained the dosing, results, and feedback he had heard firsthand from his own patients. In his takeaways for the presentation, he noted that trauma affects everyone, psilocybin therapy shows promise, and that continued research is critical.
One question from the audience focused on finding concrete information on recommended micro and macro dosing. Schwartz gave his opinion on what a microdose is and recommended working with a laboratory that can provide information on a product to ensure consistency. He emphasized that this consistency helps patients have a positive treatment experience and want to continue their treatments, giving them time to break the cycles of the disease process.
For more information on psychedelics, please check out our recent digital edition "Psychedelics: New Frontiers in Alternative Medicine."
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
